Sustained release delivery of active agents to treat glaucoma and ocular hypertension
First Claim
1. A method to reduce intraocular pressure in an eye of a patient having open angle glaucoma or ocular hypertension and a baseline intraocular pressure of 21-30 mmHg, the method comprising:
- administering to the eye of the patient having open angle glaucoma or ocular hypertension and a baseline intraocular pressure of 21-30 mmHg, an intraocular pressure-reducing therapeutic agent sustained release topical formulation, wherein the sustained release topical formulation is capable of continuously releasing the intraocular pressure-reducing therapeutic agent over at least 7 days to the eye from a punctal implant wherein the intraocular pressure is reduced at least 10% from baseline, andwherein the punctal implant comprises a first, second and intermediate portion, wherein the implant extends from a proximal end of the first portion, defining a proximal axis, to a distal end of the second portion, defining a distal axis, and when implanted, is configured with an at least 45 degree angled intersection between the proximal axis and the distal axis for biasing at least a portion of the implant against at least a portion of a lacrimal canaliculus located at or more distal to a canaliculus curvature and wherein the intermediate portion projects proximally from the intersection between the first and second implant body portions and is configured to bias against a portion of a lacrimal canaliculus ampulla.
4 Assignments
0 Petitions
Accused Products
Abstract
The methods described herein provide treatment of glaucoma, ocular hypertension, and elevated intraocular pressure with latanoprost or other therapeutic agent(s). Implant devices for insertion into a punctum of a patient provide sustained release of latanoprost or other therapeutic agent(s) that is maintained for 7, 14, 21, 30, 45, 60, or 90 days or more, thus avoiding patient noncompliance and reducing or lowering adverse events associated with eye drop administration of latanoprost or other therapeutic agent(s) and other therapeutic agent(s).
128 Citations
18 Claims
-
1. A method to reduce intraocular pressure in an eye of a patient having open angle glaucoma or ocular hypertension and a baseline intraocular pressure of 21-30 mmHg, the method comprising:
-
administering to the eye of the patient having open angle glaucoma or ocular hypertension and a baseline intraocular pressure of 21-30 mmHg, an intraocular pressure-reducing therapeutic agent sustained release topical formulation, wherein the sustained release topical formulation is capable of continuously releasing the intraocular pressure-reducing therapeutic agent over at least 7 days to the eye from a punctal implant wherein the intraocular pressure is reduced at least 10% from baseline, and wherein the punctal implant comprises a first, second and intermediate portion, wherein the implant extends from a proximal end of the first portion, defining a proximal axis, to a distal end of the second portion, defining a distal axis, and when implanted, is configured with an at least 45 degree angled intersection between the proximal axis and the distal axis for biasing at least a portion of the implant against at least a portion of a lacrimal canaliculus located at or more distal to a canaliculus curvature and wherein the intermediate portion projects proximally from the intersection between the first and second implant body portions and is configured to bias against a portion of a lacrimal canaliculus ampulla. - View Dependent Claims (2, 3, 4, 5, 6, 7, 12, 13, 14, 15)
-
-
8. A method to reduce intraocular pressure in an eye of a patient having open angle glaucoma or ocular hypertension and a baseline intraocular pressure of 21-30 mmHg, the method comprising:
-
inserting a punctal implant into at least one punctum of the eye of the patient having open angle glaucoma or ocular hypertension and a baseline intraocular pressure of 21-30 mmHg, wherein the implant comprises an intraocular pressure-reducing therapeutic agent sustained release topical formulation drug core comprising a matrix and the therapeutic agent, wherein the sustained release topical formulation is capable of continuously releasing the intraocular pressure-reducing therapeutic agent over at least 7 days to the eye wherein the intraocular pressure is reduced at least about 10% from baseline, and wherein the punctal implant comprises a first, second and intermediate portion, wherein the implant extends from a proximal end of the first portion, defining a proximal axis, to a distal end of the second portion, defining a distal axis, and when implanted, is configured with an at least 45 degree angled intersection between the proximal axis and the distal axis for biasing at least a portion of the implant against at least a portion of a lacrimal canaliculus located at or more distal to a canaliculus curvature and wherein the intermediate portion projects proximally from the intersection between the first and second implant body portions and is configured to bias against a portion of a lacrimal canaliculus ampulla. - View Dependent Claims (9, 10, 11, 16, 17, 18)
-
Specification